Introduction Chimeric antigen receptor (CAR) T-cell therapy produces high overall response rates (ORR) and can induce durable remissions in relapsed/refractory multiple myeloma (MM), raising the possibility of long-term disease control or cure. However, standard response assessments have limited ability to identify patients with exceptional outcomes early after CAR T therapy. Bone marrow-based [...]

Introduction Minimal residual disease (MRD) negativity is a key prognostic marker in multiple myeloma (MM), strongly associated with improved progression-free survival (PFS) and overall survival (OS). Current MRD assessments rely on next-generation sequencing (NGS) or next-generation flow cytometry (NGF) from bone marrow, which are invasive and may miss disease due to patchy [...]

Introduction Minimal residual disease (MRD) negativity is a critical prognostic factor in multiple myeloma (MM), but conventional monitoring relies on invasive bone marrow (BM) testing and may miss disease due to spatial heterogeneity. EasyM is a mass spectrometry-based blood assay that tracks patient-specific M-protein peptides in peripheral blood, enabling frequent, non-invasive MRD [...]